Enhancing oncolytic virotherapy with a tri-specific T-cell engager targeting CD3ε, EpCaM, and 4-1BB: preclinical evaluation and implications for cancer immunotherapy
Oncolytic adenovirus armed with TriTE enhances antitumor immunity by integrating costimulatory signaling. Incorporating costimulatory molecules into oncolytic virotherapy may offer more effective cancer immunotherapy strategies.
Authors
- Zhongyi Dong
- Haoyu Zhang (ORCID: https://orcid.org/0009-0000-5065-2937)
- Zizhen Zhang
- Muerzhate Aimaiti
- Qianyu Guo
- Shuguang Zuo
- Aya Elalfy
- Tao Liu
- Xiang Xia
- Guy Robinson
- Long Bai
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Jacksonville College (US)
- WinnMed (US)
- Liuzhou General Hospital (CN)
- Shanghai Cancer Institute (CN)
- State Key Laboratory of Oncogene and Related Genes (CN)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- BMC Medicine
- Published
- 2026-01-30
- DOI
- https://doi.org/10.1186/s12916-026-04661-x
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00